Biotech and pharma venture capitalist (VC) deal activity will likely exceed $20 billion for the second consecutive year in 2021, said research firm PitchBook.

"These two main areas for VC have grown during the COVID-19 pandemic and investors have ample dry powder to direct money at biotech and pharma firms in 2021," stated the data provider for the private and pu